# US 2003/0225092 A1 · Chemical compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0225092 A1
- Document ID: US20030225092A1
- Status: Published application
- Kind: A1
- Application number: 10/297,245
- Filed: 2002-12-03
- Published: 2003-12-04
- Earliest claimed: 2002-12-03
- Assignees: Lilly ICOS LLC
- Inventors: Mark W. Orme; Jason Scott Sawyer; Alain Claude-Marie Daugan
- Web page: https://patentgrep.com/patent/US20030225092A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 13/08: of the prostate
- A61P 13/12: of the kidneys
- A61P 15/06: Antiabortive agents; Labour repressants
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 15/10: for impotence
- A61P 19/10: for osteoporosis
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of the general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents. 1

## Claims

### Claim 1

A compound having a formula
39
wherein R1 is selected from the group consisting of hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C3-8cycloalkyl, heteroC3-8cycloalkyl, C3-8cycloalkylC1-2alkyl, arylC1-3alkyl, and heteroarylC1-3alkyl;
R2 is selected from the group consisting of an optionally substituted monocyclic aromatic ring selected from the group consisting of benzene, thiophene, furan, and pyridine, and an optionally substituted bicyclic ring
40
wherein the fused ring A is a 5- or 6-membered ring, saturated or partially or fully unsaturated, and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulfur, and nitrogen;
R3 is selected from the group consisting of hydrogen and C1-6alkyl,
or R1 and R3 together represent a 3- or 4-membered alkyl or alkenyl chain component of a 5- or 6-membered ring;
R4, independently, is selected from the group consisting of
aryl,
Het,
C3-8cycloalkyl,
YC3-8cycloalkyl (wherein Y is oxygen, sulfur, or NRa),
C(═O)Ra,
OC(═O)Ra,
C(═O)ORa,
C1-4alkyleneNRaRb,
C1-4alkyleneHet,
C1-4alkyleneC(═O)ORa,
C(═O)NRaSO2Rc,
C(═O)C1-4alkyleneHet,
C(═O)NRaRb,
C(═O)NRaRc,
C(═O)NRaC1-4alkyleneORb,
C(═O)NRaC1-4alkyleneHet,
ORa,
OC1-4alkyleneC(═O)ORa,
OC2-4alkyleneNRaRb,
OC1-4alkyleneHet,
OC2-4alkyleneORa,
OC1-4alkyleneNRaC(═O)ORb,
NRaRb,
NRaC1-4alkyleneNRaRb,
NRaC(═O)Rb,
NRaC(═O)NRaRb,
N(SO2C1-4alkyl)2,
NRa(SO2C1-4alkyl),
nitro (NO2),
trifluoromethyl,
trifluoromethoxy,
cyano (CN),
SO2NRaRb,
SO2Ra,
SRa,
and OSO2CF3;
R5 is selected from the group consisting of hydrogen, halogen, and C1-6alkyl;
or R4 and R5 are taken together with the carbon atoms to which they are attached to form a 5-, 6-, or 7-membered ring, saturated or partially or fully unsaturated, optionally substituted and optionally containing one or two heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen;
Ra is selected from the group consisting of hydrogen, C1-6alkyl, C3-8cycloalkyl, aryl, arylC1-3-alkyl, C1-3alkylenearyl, and Het;
Rb is selected from the group consisting of hydrogen, C1-6alkyl, aryl, arylC1-3alkyl, C1-2alkylenearyl, and Het;
Rc is phenyl or C4-6cycloalkyl, either optionally substituted with one or more substituent selected from the group consisting of halo, C(═O)ORa, and ORa;
Het is a 5- or 6-membered heterocyclic group, saturated or partially or fully unsaturated, containing at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, and optionally substituted with C1-4alkyl or C(═O)ORb;
q is 1, 2, or 3; and
pharmaceutically acceptable salts and hydrates thereof.

### Claim 2 (depends on 1)

The compound of claim 1 represented by the formula
41
and pharmaceutically acceptable salts and solvates thereof.

### Claim 3 (depends on 1)

The compound of claim 1 wherein R1 is selected from the group consisting of hydrogen, C1-4alkyl, haloC1-4alkyl, C3-6cycloalkyl, and C3-6cycloalkylmethyl.

### Claim 4 (depends on 1)

The compound of claim 1 wherein R3 is hydrogen.

### Claim 5 (depends on 1)

The compound of claim 1 wherein R2 is an optionally substituted bicyclic ring selected from the group consisting of naphthalene, indene, benzoxazole, benzothiazole, benzisoxazole, benzimidazole, quinoline, indole, benzothiophene, and benzofuran.

### Claim 6 (depends on 1)

The compound of claim 1 wherein R2 is
42
and wherein n is an integer 1 or 2, and X, independently, are C(Ra)2, O, S, or NRa.

### Claim 7 (depends on 1)

The compound of claim 1 wherein R2, substituted or unsubstituted, is selected from the group consisting of
43

### Claim 8 (depends on 7)

The compound of claim 7 wherein R2 is substituted with a substituent selected from the group consisting of halogen, C1-3alkyl, ORa, CO2Ra, halomethyl, halomethoxy, cyano, nitro, and NRaRb.

### Claim 9 (depends on 1)

The compound of claim 1 wherein R4 is selected from the group consisting of aryl, trifluoromethyl, trifluoromethoxy, C(═O)Ra, C(═O)ORa, C(═O)NRaRb, C(═O)NRaRc, ORa, CN, C1-4alkyleneNRaRb, OC2-4alkyleneNRaRb, SO2NRaRb, OC(═O)Ra, NRaRb, Het, C3-8-cycloalkyl, and C3-8cycloalkylY.

### Claim 10 (depends on 9)

The compound of claim 9 wherein R4 is selected from the group consisting of CH2NRaRb, aryl, CN, ORa, C(═O)ORa, and NRaRb.

### Claim 11 (depends on 10)

The compound of claim 10 wherein R4 is selected from the group consisting of CH2NH2, CO2H, CO2CH3, C6H5, OCH2C6H5, OH, CN, and OCH3.

### Claim 12 (depends on 1)

The compound of claim 1 wherein R1 and R5 are taken together to form a 6-membered saturated or unsaturated ring, optionally substituted and optionally containing one or two heteroatoms.

### Claim 13 (depends on 12)

The compound of claim 12 wherein R4 and R5 are taken together to form a phenyl ring.

### Claim 14 (depends on 1)

The compound of claim 1 wherein R5 is hydrogen.

### Claim 15

A compound selected from the group consisting of
44 45 46 47
and pharmaceutically acceptable salts and solvates thereof.

### Claim 16 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, together with a pharmaceutically acceptable diluent or carrier.

### Claim 17 (depends on 1)

A method of treating a male or female animal in the treatment of a condition where inhibition of a cGMP-specific PDE is of a therapeutic benefit comprising treating said animal with an effective amount of a pharmaceutical composition comprising a compound of claim 1, together with a pharmaceutically acceptable diluent or carrier.

### Claim 18 (depends on 17)

The method of claim 17 wherein the condition is male erectile dysfunction.

### Claim 19 (depends on 18)

The method of claim 18 wherein the treatment is an oral treatment.

### Claim 20 (depends on 17)

The method of claim 17 wherein the condition is female sexual arousal disorder.

### Claim 21 (depends on 20)

The method of claim 20 wherein the treatment is an oral treatment.

### Claim 22 (depends on 17)

The method of claim 17 wherein the condition is selected from the group consisting of stable angina, unstable angina, variant angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, malignant hypertension, pheochromocytoma, acute respiratory distress syndrome, congestive heart failure, acute renal failure, chronic renal failure, atherosclerosis, a condition of reduced blood vessel patency, a peripheral vascular disease, a vascular disorder, thrombocythemia, an inflammatory disease, myocardial infarction, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, peptic ulcer, a gut motility disorder, postpercutaneous transluminal coronary angioplasty, carotid angioplasty, post-bypass surgery graft stenosis; osteoporosis, preterm labor, benign prostatic hypertrophy, and irritable bowel syndrome.

### Claim 23 (depends on 1)

A method of treating a condition where inhibition of a cGMP-specific PDE is of therapeutic benefit, in a human or a nonhuman animal body, comprising administering to said body a therapeutically effective amount of a compound of claim 1.

### Claim 24 (depends on 1)

A method for the curative or prophylactic treatment of male erectile dysfunction or female sexual arousal disorder, comprising administration of an effective dose of a compound of claim 1, and pharmaceutically acceptable salts and solvates thereof, to an animal.

### Claim 25 (depends on 1)

Use of a compound of claim 1 for the manufacture of a medicament for the curative or prophylactic treatment of a condition where inhibition of a cGMP-specific PDE is of a therapeutic benefit.
